210 related articles for article (PubMed ID: 12600812)
21. Levetiracetam: a long-term follow-up study of efficacy and safety.
Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG
Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344
[TBL] [Abstract][Full Text] [Related]
22. Tiagabine (gabitril) experience in children.
Pellock JM
Epilepsia; 2001; 42 Suppl 3():49-51. PubMed ID: 11520324
[TBL] [Abstract][Full Text] [Related]
23. Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy.
Sorri I; Kälviäinen R; Mäntyjärvi M
Epilepsy Res; 2005 Dec; 67(3):101-7. PubMed ID: 16257182
[TBL] [Abstract][Full Text] [Related]
24. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment.
Eckardt KM; Steinhoff BJ
Epilepsia; 1998 Jun; 39(6):671-4. PubMed ID: 9637612
[TBL] [Abstract][Full Text] [Related]
25. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study).
Lossius MI; Hessen E; Mowinckel P; Stavem K; Erikssen J; Gulbrandsen P; Gjerstad L
Epilepsia; 2008 Mar; 49(3):455-63. PubMed ID: 17888074
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.
Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229
[TBL] [Abstract][Full Text] [Related]
27. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
28. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
[TBL] [Abstract][Full Text] [Related]
29. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
Specchio LM; Gambardella A; Giallonardo AT; Michelucci R; Specchio N; Boero G; La Neve A
Epilepsy Res; 2006 Sep; 71(1):32-9. PubMed ID: 16814521
[TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.
Pieribone VA; Tsai J; Soufflet C; Rey E; Shaw K; Giller E; Dulac O
Epilepsia; 2007 Oct; 48(10):1870-4. PubMed ID: 17634060
[TBL] [Abstract][Full Text] [Related]
31. Non-convulsive status epilepticus in two patients receiving tiagabine add-on treatment.
Skodda S; Kramer I; Spittler JF; Gehlen W
J Neurol; 2001 Feb; 248(2):109-12. PubMed ID: 11284127
[TBL] [Abstract][Full Text] [Related]
32. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study.
Uldall P; Bulteau C; Pedersen SA; Dulac O; Lyby K
Epilepsy Res; 2000 Dec; 42(2-3):159-68. PubMed ID: 11074188
[TBL] [Abstract][Full Text] [Related]
33. Seizure activity and off-label use of tiagabine.
Flowers CM; Racoosin JA; Kortepeter C
N Engl J Med; 2006 Feb; 354(7):773-4. PubMed ID: 16481654
[No Abstract] [Full Text] [Related]
34. [Experience with tiagabine in the clinical practice; new insights as to the efficacy and safety profile].
Kellinghaus C; Loddenkemper T; Weitemeyer L; Lüdemann P
Nervenarzt; 2001 Oct; 72(10):764-9. PubMed ID: 11688177
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
36. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.
Sachdeo RC; Leroy RF; Krauss GL; Drake ME; Green PM; Leppik IE; Shu VS; Ringham GL; Sommerville KW
Arch Neurol; 1997 May; 54(5):595-601. PubMed ID: 9152116
[TBL] [Abstract][Full Text] [Related]
37. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
Genton P; Sadzot B; Fejerman N; Peltola J; Despland PA; Steinhoff B; Rektor I; Wroe S; Maubrey MC; Vandervelden C; van Hammée G; Schlit AF; van Paesschen W
Acta Neurol Scand; 2006 Jun; 113(6):387-94. PubMed ID: 16674605
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of antiepileptic drugs in an Omani epileptic population.
Hanssens Y; Al-Asmi A; Al-Busaidi I; Deleu D
Clin Neurol Neurosurg; 2006 Sep; 108(6):532-8. PubMed ID: 16169660
[TBL] [Abstract][Full Text] [Related]
39. Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria.
Piccinelli P; Borgatti R; Perucca E; Tofani A; Donati G; Balottin U
Epilepsia; 2000 Nov; 41(11):1485-8. PubMed ID: 11077464
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?
Zaccara G; Messori A; Cincotta M; Burchini G
Acta Neurol Scand; 2006 Sep; 114(3):157-68. PubMed ID: 16911343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
